Cabaletta Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Insider Trading Arrangements

Insider Trading Arrangements

3 Months Ended

Mar. 31, 2024

Rule 10b5-1 Trading Plans

During the fiscal quarter ended on March 31, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K, except as described in the table below:

      Name and Title

      Action

      Action Date

      Duration of Trading Arrangements(1)

      Rule 10b5-1 Trading Arrangement?
(Y/N)*

      Aggregate Number of Securities Subject to Trading Arrangement

      Michael Gerard
General Counsel

      Adopt

      February 21, 2024

      August 1, 2024 – August 6, 2025

      Y

      Up to 46,875 shares to be sold

* Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).

(1) Except as indicated by footnote, each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.

Rule 10b5-1 Arrangement Adopted

false

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Rule 10b51 Arr Modified Flag

false

Non Rule 10b51 Arr Modified Flag

false